FORGING RUSSIAN MARKET INROADS
Taigen Biotechnology inks licensing deal with R-Pharm, raises $36.4M in Taiwan IPO
By Shannon Ellis
Wednesday, January 22, 2014
SHANGHAI – A new licensing deal is giving Taiwan’s Taigen Biotechnology Co. inroads into the large Russian market just as the parent company’s shares started trading in Taiwan.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.